Biopharma company developing affinity enhanced T cell receptor (TCR) engineered T cells to treat hematologic and solid tumor cancers.
- Year invested 2014
- Investment Stage Early
- Board Members
- Sectors
- Investment Status Current
- Website adaptimmune.com
- Company Status IPO/Public (Nasdaq: ADAP)